36 / 37
TAKE HOME MESSAGES
Treatment landscape has dramatically evolved during the last
years
No definitive predictive biomarkers are available. Decisions
are taken based on clinic-pathological features
Classical RECIST criteria may be not enough to evaluate the
efficacy of all drugs for NETs
Sequential therapies are used in routine clinical practice
even the lack of evidence for the best sequence